Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2RL1 | P55085 | 19/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2887479 | 0.84 | — | — | |
| SCHEMBL2205006 | 0.81 | F2RL1 (0.48) | F2RL1 | |
| SCHEMBL23863035 | 0.80 | — | — | |
| SCHEMBL27550578 | 0.80 | — | — | |
| SCHEMBL321153 | 0.80 | — | — | |
| SCHEMBL7676472 | 0.80 | CYP17A1 (0.46) | F2RL1 | |
| SCHEMBL7868086 | 0.79 | ALDH1A1 (0.40) | F2RL1 | |
| Hydrochloric Acid SCHEMBL11544931 | 0.78 | ADRA2A (0.45) | F2RL1 | |
| SCHEMBL30229840 | 0.78 | F2RL1 (0.50) | F2RL1 | |
| SCHEMBL4909884 | 0.78 | F2RL1 (0.49) | F2RL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0358377-B1 | BIS IMIDAZOLE ETHERS AS METAL DEACTIVATORS | EXXON RESEARCH AND ENGINEERING COMPANY (US) | 1993-04-28 | — | — | EP | claimed |
| WO-2025125666-A1 | SUBSTITUTED IMIDAZOLES AS INHIBITORS OF NAV1.8 | Grünenthal GmbH (DE) | 2025-06-19 | — | — | WO | disclosed |
| US-11339144-B2 | Heteroaryl Rheb inhibitors and uses thereof | NAVITOR PHARMACEUTICALS, INC. (US) | 2022-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11339144-B2 | Heteroaryl Rheb inhibitors and uses thereof | RHEB, GDI2, KRAS | F2RL1 3089/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.